Register to receive a free Europe Market Report Suite for Patient Monitoring Equipment report synopsis and brochure
Masimo (MASI) announced today the CE mark and scheduled full market release of Next Generation SedLine® Brain Function Monitoring technology at the European Society of Anaesthesiology’s (ESA) 2016 Euroanaesthesia Congress in London, England.
Next Generation SedLine enhances how Masimo’s processed EEG parameter, the Patient State Index (PSI), responds in challenging situations, addressing many of the concerns raised with quantitative EEG while bolstering brain function monitoring’s support of anesthetic management.
Next Generation PSI uses Masimo’s breakthrough Parallel Engines and Adaptive Signal Processing technology and provides the following enhancements:
- Less susceptibility to electromyography (EMG) interference by extracting a clearer EEG signal even in the presence of EMG
- Improved PSI performance in low power EEG cases
These improvements build upon the existing benefits of SedLine technology:
- Four simultaneous EEG leads to enable continuous assessment of both sides of the brain
- Density Spectral Array (DSA) offers easy-to-interpret, high-resolution display of bi-hemispheric activity
- Multiple screen views expand information while enabling customization in the OR and ICU
- Electrocautery resistance
“We are delighted to unveil Next Generation SedLine,” said Joe Kiani, Founder and CEO of Masimo. “Next Generation PSI takes advantage of Masimo’s signal processing prowess and promises to do for brain function monitoring what SET did for pulse oximetry.”
Next Generation SedLine has not received FDA 510(k) clearance and is not currently available for sale in the United States.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect (MOC-9) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.
For Further Information
More on the patient monitoring device market in Europe can be found in a report suite published by iData Research entitled Europe Market Report Suite for Patient Monitoring Equipment. The suite covers reports on the following markets: MULTI-PARAMETER VITAL SIGNS MONITORING MARKET, WIRELESS AMBULATORY TELEMETRY MONITOR MARKET, CARDIAC OUTPUT MONITORING MARKET, ELECTROMYOGRAM MONITORING MARKET, ELECTROENCEPHALOGRAM MONITORING MARKET, FETAL AND NEONATAL MONITORING MARKET, PERIPHERAL PULSE OXIMETER MARKET, and TELEHEALTH MARKET.
The iData report series on patient monitoring devices covers the United States, Japan, Australia, South Korea, and 15 countries in Europe. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about patient monitoring market data or procedure data, register online or email us at [email protected] for a Europe Market Report Suite for Patient Monitoring Equipment brochure and synopsis.
About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.
About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.
Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.